Atrial Fibrillation (AFib) Support Group
Atrial fibrillation (AF or afib) is an abnormal heart rhythm (cardiac arrhythmia) which involves the two small, upper heart chambers (the atria). Heart beats in a normal heart begin after electricity generated in the atria by the sinoatrial node spread through the heart and cause contraction of the heart muscle and pumping of blood.
Wish you the best,
Scott
--jeff
Hugs.
Christine
We made it through the surgery successfully. The surgeon showed me a picture of the calcified valve and the portion of muscle they took off. They were able to extubate him pretty quickly, and he was resting comfortably with the pain managed this evening. It will take a couple of days to see how his "pacing" goes, but for now things are stable and good. He even cracked a few jokes between sleeping. We know we have a long road ahead, but we are so happy that day one is over. Thank you for your support. I will keep you updated. Praying, too, that the AFIB stays away...
Hope everything continues to go smoothly:) Prayers confined and NO AFIB. Hope you both get some well needed rest.
Hugs;
Christine
Tami
Here is a quote:
"Atrial fibrillation (A-fib) is a relatively common complication of both surgical (SAVR) and transcatheter-based (TAVR) aortic valve replacement (AVR), according to a single-center, retrospective cohort study appearing online January 29, 2014, ahead of print in the Journal of the American College of Cardiology."
There were 123 patients in the study.
" Single-center study: New-onset A-fib occurred in 42.3% of AVR patients
A-fib occurred almost twice as often with SAVR (60%) as with TAVR (35%)
New-onset A-fib occurred at a median time of 53 hours56 hours in the SAVR group and 52 hours in the TAVR group. More than half of A-fib episodes lasted less than 24 hours and spontaneously resolved. Twenty-five patients received amiodarone, including 2 patients who eventually underwent successful electrical cardioversion. Conversion after administration of amiodarone occurred in the majority of patients who received the drug, but 11 patients remained in A-fib at the time of discharge and 7 remained in A-fib at 30-day follow-up."